ImmunityBio, Inc.
2 clinical trials · 2 recruiting · INDUSTRY
Trials by ImmunityBio, Inc.
RECRUITINGPhase 2NCT06710288
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In...
This is phase 2 single arm study evaluating the safety and preliminary efficacy of M-CENK adoptive cell therapy and fixed dose of N-803 in combination with gemcitabine in...
Sponsor: ImmunityBio, Inc.Enrolling: 202 locations
Platinum-resistant Ovarian Cancer
RECRUITINGPhase 2NCT07123727
A Study to Examine Anktiva for the Treatment of COVID-19.
This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain...
Sponsor: ImmunityBio, Inc.Enrolling: 401 location
Long COVIDLong COVID SyndromeLong Covid 19